Motilal Oswal fund sells 2% of Molbio Diagnostics for ₹306 crore
Kalpana Maurya
1 Oct 2026 · 2 min read
Business Excellence Trust III, a Motilal Oswal Alternates fund, sold a little over 2% of Molbio Diagnostics for ₹306 crore in open-market deals on 30 September 2026, with HDFC Mutual Fund picking up a similar block. It is the fund's second sale in the stock in a week.
Motilal Oswal Alternates has sold a little over 2% of Goa-based Molbio Diagnostics for about ₹306 crore through open-market transactions on Wednesday, 30 September 2026, according to BSE bulk-deal data reported by PTI.
The seller was Business Excellence Trust III, a fund managed by Motilal Oswal Alternates. It sold 23.28 lakh shares at an average of ₹1,315.01 each, for a total of ₹306.26 crore.
Who bought
HDFC Mutual Fund bought 23 lakh Molbio shares, about a 2% stake, at an average price of ₹1,315 apiece, paying ₹302.45 crore. The exchange data did not identify the other buyers. Whalesbook, which tracked the day's bulk deals, described HDFC Mutual Fund's purchase as a new position of 1.99%.
Molbio's shares rose 4.07% to close at ₹1,309.45 on the BSE that day.
A second sale in a week
Business Excellence Trust III held 11.52% of Molbio as of August 2026. A week earlier it had sold a 2.6% stake in the company for ₹394 crore. With this latest sale of just over 2%, the fund has now reduced its holding twice in quick succession, though it remains a significant shareholder on the reported numbers.
Taken together, the two transactions add up to roughly 4.6% of Molbio sold for about ₹700 crore in the space of a week. The average price in the latest sale, ₹1,315.01, was a little above the stock's closing price of ₹1,309.45 that day.
No reason for the sale was given in the reports, and neither Motilal Oswal Alternates nor Molbio commented on the transactions in the coverage reviewed.
About Molbio Diagnostics
Molbio Diagnostics is a listed diagnostics company based in Goa. Its shares trade on the BSE, where the bulk deals were recorded.
Other bulk deals the same day
In a separate transaction on 30 September, Gian Parkash Aggarwal sold 15.50 lakh shares, or 2.71%, of pharmaceutical company Innova Captab for ₹167 crore at an average of ₹1,080.04 per share. SBI Mutual Fund bought 8.33 lakh shares, about 1.45%, for ₹90 crore. Innova Captab's shares fell 9% to close at ₹1,158.15 on the BSE.
Key facts
- Company: Molbio Diagnostics, Goa
- Seller: Business Excellence Trust III (Motilal Oswal Alternates)
- Shares sold: 23.28 lakh, a little over 2%
- Average price: ₹1,315.01 per share
- Value: ₹306.26 crore
- Buyer named: HDFC Mutual Fund, 23 lakh shares (about 2%) for ₹302.45 crore
- Seller's prior stake: 11.52% as of August 2026
- Closing price: ₹1,309.45, up 4.07%
- Date: 30 September 2026
Frequently asked questions
How much of Molbio Diagnostics did Motilal Oswal Alternates sell?
Its fund Business Excellence Trust III sold 23.28 lakh shares, a little over 2%, for ₹306.26 crore on 30 September 2026.
Who bought the Molbio shares?
HDFC Mutual Fund bought 23 lakh shares, about 2%, for ₹302.45 crore. Other buyers were not identified.
Has the fund sold Molbio shares before?
Yes. A week earlier, Business Excellence Trust III sold a 2.6% stake for ₹394 crore.
How did Molbio's stock react?
The shares closed 4.07% higher at ₹1,309.45 on the BSE.
